SCRIB and neoplasm: Mechanistically compelling candidates also included bortezomib, which stabilizes p53 and PDZ-domain tumor suppressors (hDlg, hScrib) to counteract HPV oncoproteins [64,65], producing synergistic tumor regression when combined with cisplatin in HeLa xenografts [93].